Raslová, Katarina <br/><br/>
Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index.  [electronic resource] 

 -  Clinical drug investigation  2007 
 - 279-85 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1173-2563 
<br/><br/><label>Standard No.: </label>10.2165/00044011-200727040-00007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Body Mass Index<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Insulin--analogs & derivatives<br/>Insulin Detemir<br/>Insulin, Long-Acting<br/>Male<br/>Middle Aged<br/>Weight Gain--drug effects